TD Cowen Remains a Buy on Biogen (BIIB)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
pharmaphorum2d
Biogen protects Tecfidera via $1.25bn deal with Forward
Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...
FierceBiotech29d
Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects
Biogen finished a phase 1 trial of the drug candidate, BIIB113, in 2023. Work on another tau-focused treatment of early Alzheimer’s, the phase 2 antisense oligonucleotide BIIB080, is continuing.
Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a seven-day winning streak.
Reuters1mon
Biogen's 2025 forecasts hit by declining sales for MS drugs, strong dollar
Biogen shares have lost more than 40% of their ... Thai lawsuit targets Charoen Pokphand Foods over invasive fish impact 1:42 PM UTC · Updated ago Autos & Transportationcategory AutoZone misses ...
MarketBeat on MSN21d
Biogen Stock Is Mutating Into a Value Play
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Yahoo Finance1mon
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
Here’s what to look for. Biogen beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $2.47 billion, down 2.5% year on year. It was a satisfactory quarter for the ...
Morningstar29d
Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow
Biogen has an Ionis-partnered pipeline to follow Spinraza in areas including Parkinson's (phase 1 LRRK2) and Alzheimer's (antisense tau drug BIIB080). 2020 collaborations with Denali in ...